NEW DELHI : The Ministry of Health and Family Welfare said on Wednesday that India has climbed an unprecedented peak with active coronavirus cases falling below the 5 lakh mark for the first time after 106 days.
In a tweet this morning, the Ministry of Health said that it takes on significance in the context of many countries reporting an increase in their number of active cases.
Active Covid Cases Below 5 Lakh Mark Finally
“This historic achievement has been made possible by the sustained, graduated and focused strategies of the Center, its effective implementation by the States and UT, the dedicated and selfless service of the doctors and all other COVID-19 warriors,” added the Ministry of Health.
The main medical body, the Indian Council of Medical Research, said that as of November 10, a total of 12,07,69,151 samples have been analyzed for the Covid-19 pandemic. Of these, 11,53,294 samples were analyzed yesterday, ICMR said.
Covid-19 vaccine in India
US drugmaker Pfizer is in talks with the Indian government to sell its promising coronavirus vaccine in the country, and believes its candidate has the potential to be an important part of India’s initial response to the vaccine, a spokesperson said. from Pfizer India in a statement to mint.
“We remain committed to advancing our dialogue with the Government of India to make this vaccine available for use in the country,” said a spokesperson for Pfizer India.
Few central government officials also said India is in talks with Pfizer for its messenger RNA vaccine, along with several other domestic and foreign developers of promising vaccine candidates.
Pfizer expects to produce up to 50 million doses of vaccines this year and up to 1.3 billion doses next year.
“If our candidate vaccine is successful, Pfizer would distribute available doses in countries where we have fully executed supply agreements,” said a Pfizer spokesperson.
Earlier on November 9, Pfizer and its German partner BioNTech announced that their vaccine candidate, BNT162b2, has prevented more than 90% of infections in a study of tens of thousands of volunteers in phase 3 trials, the most scientific advance. encouraging so far in battle. against the coronavirus.
Pfizer and BioNTech SE became the first drug manufacturers to show successful data from a large-scale clinical trial of a coronavirus vaccine.
.
